Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in Crispr Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 420 shares of the company’s stock, valued at approximately $26,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. NEXT Financial Group Inc increased its holdings in Crispr Therapeutics by 915.0% in the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares during the last quarter. Coastal Investment Advisors Inc. purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth $26,000. US Bancorp DE grew its stake in shares of Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares in the last quarter. FinTrust Capital Advisors LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth $51,000. Finally, Griffin Asset Management Inc. purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth $64,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
A number of equities analysts have commented on CRSP shares. Goldman Sachs Group lifted their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Chardan Capital reissued a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Finally, Canaccord Genuity lifted their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $71.38.
In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.
Shares of CRSP opened at $58.33 on Friday. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.29 billion, a P/E ratio of -16.96 and a beta of 3.20. The firm has a 50-day moving average price of $65.14 and a 200 day moving average price of $52.14. Crispr Therapeutics AG has a 12-month low of $29.34 and a 12-month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Equities research analysts predict that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: How is diluted EPS different from basic EPS?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.